JC Landry

DocwireNews

Patients with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD) often experience hyperphosphatemia. Due primarily to the progressive inability of the kidneys to appropriately excrete phosphorus, disrupted phosphorus homeostasis leads to phosphorus accumulation. There have been associations between high levels of serum phosphorus and increased risk of cardiovascular morbidity and mortality. In a previous large national study, the risk of mortality among patients with CKD receiving hemodialysis therapy increased by 6% for each 1 mg/dL increase in serum phosphate level above the Kidney Disease Outcomes Quality Initiative target of 3.5 to 5.5 mg/dL.Oral phosphate binders are effective in lowering serum phosphate. However, those agents have high pill burdens and low adherence rates. There is an association between reduced adherence to prescribed phosphate binder therapy and increased concentrations of serum phosphorus.Sucroferric oxyhydroxide (SO; Velphoro&reg; [Fresenius Medical Care Renal Therapies Group, Waltham, MA]) is a noncalcium, chewable, iron-based phosphate binder indicated for treating hyperphosphatemia in patients on dialysis therapy. Previous studies have shown similar efficacy, good tolerability, and lower pill burden when compared with sevelamer carbonate.Results of a recent 6-month retrospective analysis of pharmacy data of patients on hemodialysis prescribed SO as part of routine care showed a &gt;50% decrease in pill burden and a 95% increase in the proportion of patients with serum phosphorus levels of &lt;5.5 mg/dL.&nbsp;Jessica Kendrick, MD, MPH, and colleagues conducted historical cohort analyses of de-identified electronic medical records to examine the long-term real-world effectiveness of SO in the management of serum phosphorus levels over a 1-year period in patients receiving&nbsp; hemodialysis. Results were reported online in the&nbsp;Journal of Renal&nbsp;Nutrition [doi.org/10.1053/j.jrn.2018.11.002].The analysis included comparisons between the 91-day period prior to SO initiation (baseline) and four consecutive 91-day intervals of SO treatment (Q1-Q4). Clinical measures included achievement of target phosphorus levels (&le;5.5 mg/dL) and the mean number of phosphate binder pills per day. The analysis included adult (age &ge;18 years) in-center hemodialysis patients from Fresenius Kidney Care units who switched from another phosphate binder to SO therapy as part of routine care between March 2014 and March 2015.There were 3110 patients who met the criteria during the analysis period. Of those, 2580 were excluded due to changing dialysis facilities (n=201), non-continuous SO prescription days (n=785), prescription of combination phosphate binder therapy with SO (n=1024), or switching to a new phosphate binder (n=570).Of the 530 adults in the analytic cohort, 41.0% (n=217) were black/African American and 16.4% (n=87) were Hispanic/Latino. All patients received hemodialysis three times per week. During baseline, the patients were prescribed monotherapy with sevelamer (59.8%), calcium acetate (27.6%), lanthanum carbonate (7.9%), or magnesium carbonate (0.4%) or were switched among those agents over the 3-month period.In the month prior to the switch to SO, 18.7% of patients had in-range serum phosphorus concentrations (&le;5.5 mg/dL). During the period of SO therapy, as many as 39.8% met that criterion, for a 113% increase in patients achieving target serum phosphorus goals. In the month prior to SO therapy, mean pill burden was 8.7 pills per day. Relative to that month, there was an association between SO therapy and at least a 49% reduction in mean pill burden during each subsequent month. Over the year of SO therapy, the mean SO pill burden was uptitrated from 4.0 at months 1 and 2 to 4.4 at month 12.At baseline, the mean serum phosphorus concentration was 6.83 and only 17.7% of the patients in the analysis cohort had attained a serum phosphorus level of &le;5.5 mg/dL on their phosphate binder. Following the switch to SO, at each follow-up quarter, there was an improvement in mean serum phosphorus level from baseline: 6.54 mg/dL at Q1, 6.37 mg/dL at Q2, 6.25 mg/dL at Q3, and 6.19 mg/dL at Q4 (P&lt;.0001 vs baseline).The proportion of patients who achieved target serum phosphorus levels was higher than baseline throughout the SO treatment period: 24.5% at Q1, 30.5% at Q2, 36.4% at Q3, and 36.0% at Q4 (P&lt;.001 for each quarter vs baseline). In further analyses, the proportions of patients reaching serum phosphorus concentrations &le;4.5 mg/dl increased from 4.7% at baseline to 6.6% at Q1, 11.6% at Q2, 12.1% at Q3, and 13.7% at Q4 (P&lt;.001 for each interval vs baseline). Overall, there was a reduction in pill burden from baseline of approximately 50% for each 91-day interval during the treatment period (Q1 through Q4:4.0-4.3;&nbsp;P&lt;.001 for each interval vs baseline).When analyzed by prespecified subgroups of interest (black/African American patients, Hispanic/Latino patients, women), findings regarding the effectiveness of SO were similar.The researchers cited some limitations to the study, including the retrospective design and lack of a comparator group followed up during the same study period, the reasons for switching from baseline phosphate binder to SO not being available, not accounting for specific nutritional education or advice given to patients, and lack of data on the use of protein supplements.&ldquo;In conclusion, results from this study demonstrate that completion of 1 year of treatment with SO was effective in controlling hyperphosphatemia in patients on hemodialysis with fewer prescribed pills per day than other PBs,&rdquo; the researchers said.Funding for the analysis was provided by Fresenius Medical Care Renal Therapies Group.Takeaway Points<ol>
<li>Researchers conducted historical cohort analyses to examine the real-world effectiveness of sucroferric oxyhydroxide (SO), a phosphate binder with a low pill burden, in managing serum phosphorus in patients prescribed SO as part of routine care.</li>
<li>Over a 1-year period, among 530 patients in the analyzed cohort, the proportion of patients achieving target serum phosphorus levels (&le;5.5 mg/dL) increased by &gt;100% after switching to SO therapy; reductions were seen at all follow-up timepoints.</li>
<li>Baseline pill burden was 8.5 pills/day. During treatment with SO, patients experienced an average 50% reduction in pill burden (Q1 through Q4: 4.0-4.3;&nbsp;P&lt;.001 for each interval vs baseline).</li>
</ol>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Real-World Long-Term Effectiveness of Sucroferric Oxyhydroxide in Managing Hyperphosphatemia

Oncology

Patients with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD) often experience hyperphosphatemia. Due primarily to the progressive inability of the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe